SCHEMBL4280081

SCHEMBL4280081

NC1=NC(N)(c2ccc(Cl)cc2)C=C(c2ccccc2)N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.37
BACE1 P56817 2/20 0.37
BACE2 Q9Y5Z0 2/20 0.37
CTSD P07339 1/20 0.37
DPP4 P27487 1/20 0.35
MECP2 P51608 1/20 0.34
MBD2 Q9UBB5 1/20 0.34
MAP4K4 O95819 1/20 0.34
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NR4A1 P22736 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
APAF1 O14727 1/20 0.33
SCN2A Q99250 1/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282261 0.79 HSD11B1 (0.39) BACE1DPP4LMNAL3MBTL1
SCHEMBL4280058 0.78 HTR2B (0.39) BACE1LMNAMAPTSMN1; SMN2
SCHEMBL4282686 0.78 CYP1A2 (0.39) CYP1A2DPP4LMNAGAAKMT2A
SCHEMBL4291033 0.71 AGPAT2 (0.43) MAP4K4
SCHEMBL4282568 0.69 ALDH1A1 (0.41) LMNAKDM4EL3MBTL1KMT2AMEN1
SCHEMBL2323802 0.68 MECP2 (0.35) CYP1A2BACE1BACE2CTSDDPP4
SCHEMBL4280084 0.68 CYP1A2 (0.35) CYP1A2BACE1BACE2CTSDDPP4
SCHEMBL15757591 0.67 HTR5A (0.33) BACE1BACE2KDM1A
SCHEMBL2323806 0.66 CYP1A2 (0.36) CYP1A2BACE1BACE2CTSDMECP2
SCHEMBL8664748 0.63 CYP1A2 (0.48) CYP1A2BACE1BACE2CTSDMECP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT CYP1A2 4325/4885BACE1 3568/4885BACE2 3023/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT CYP1A2 4519/4885BACE1 2395/4885BACE2 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.